risperidone has been researched along with Body Weight in 109 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aripiprazole and risperidone are the only FDA approved medications for treating irritability in autistic disorder, however there are no head-to-head data comparing these agents." | 9.19 | A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. ( Berk, M; Ghanizadeh, A; Sahraeizadeh, A, 2014) |
| "The present study aimed to examine the changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia." | 9.19 | Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia. ( Fan, X; Gao, J; Harrington, A; Li, X; Lv, L; Song, X; Zhang, W; Zhao, J; Ziedonis, D, 2014) |
| " Our research group is developing a non-commercial, multicentric and open label study on the differential efficacy between clozapine and risperidone in first-episode schizophrenia." | 9.17 | Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year. ( Aragües, M; Del Alamo, C; Molina, V; Ovejero, S; Palomo, T; Sanz-Fuentenebro, J; Taboada, D, 2013) |
| "The purpose of this study is to compare the efficacy of olanzapine and risperidone for the acute treatment of first-episode schizophrenia patients with cannabis use disorders." | 9.15 | Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. ( Kane, J; McCormack, J; Miller, R; Napolitano, B; Robinson, DG; Sevy, S; Sunday, S, 2011) |
| "This study aimed to characterize weight changes in schizophrenia patients taking risperidone as part of a randomized, controlled, open-label clinical trial." | 9.15 | Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia. ( Bo, QJ; Chiu, HF; Dixon, LB; Kreyenbuhl, JA; Lai, KY; Lee, EH; Ungvari, GS; Wang, CY; Xiang, YT, 2011) |
| "The purpose of this double-blind, placebo-controlled exploratory pilot study was to evaluate the safety and efficacy of risperidone for the treatment of anorexia nervosa." | 9.15 | A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. ( Dodge, M; Ellert, S; Frank, G; Gardner, R; Gralla, J; Hagman, J; O'Lonergan, T; Sigel, E; Wamboldt, MZ, 2011) |
| "Eight patients with psychotic disorders (ages 11-17) who had started risperidone (mean: 1." | 9.14 | Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. ( Maayan, LA; Vakhrusheva, J, 2010) |
| "The current study evaluated the efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia." | 9.13 | Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. ( Casey, DE; Heisterberg, J; Sands, EE; Yang, HM, 2008) |
| "This open-label, prospective, 4-month study in hyperprolactinemic patients with schizophrenia explored whether prolactin levels decrease after switching antipsychotic therapy to olanzapine." | 9.12 | Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. ( Ahl, J; Kinon, BJ; Liu-Seifert, H; Maguire, GA, 2006) |
| "Among this group of patients with chronic schizophrenia who had just discontinued treatment with an atypical antipsychotic, risperidone and olanzapine were more effective than quetiapine and ziprasidone as reflected by longer time until discontinuation for any reason." | 9.12 | Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. ( Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS, 2006) |
| "Subjects were patients with schizophrenia or schizoaffective disorder enrolled in extension studies (Study A and Study B) after participating in 12-week studies of long-acting injectable risperidone [Kane, J." | 9.12 | Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. ( Eerdekens, M; Khan, A; Kushner, S; Lindenmayer, JP; Van Hove, I, 2007) |
| "Risperidone may be effective in improving tantrums, aggression, or self-injurious behaviour in children with autism, but often leads to weight gain." | 9.12 | Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study. ( Aman, MG; Bozzolo, D; Eugene Arnold, L; Lindsay, RL; McCracken, JT; McDougle, CJ; Pachler, M; Posey, DJ; Scahill, L; Tierney, E; Vitiello, B, 2006) |
| "Weight change was measured for 63 children and adolescents with autism treated with risperidone for 6 months." | 9.11 | Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. ( Aman, M; Anderson, GM; Arnold, LE; Chuang, S; Martin, A; McCracken, J; McDougle, CJ; Scahill, L; Tierney, E; Vitiello, B, 2004) |
| "These pilot data, from the first prospective comparison study of risperidone and olanzapine in bipolar disorder, suggest that adjunctive administration of either agent may reduce depressive symptom severity." | 9.11 | The antidepressant effects of risperidone and olanzapine in bipolar disorder. ( Kennedy, SH; Konarski, JZ; Mancini, DA; McCann, S; McIntyre, RS; Srinivasan, J, 2004) |
| "The aim of this article was to examine the effects of switching from the antipsychotic olanzapine to risperidone on the prevalence of the metabolic syndrome in high-risk overweight or obese patients with schizophrenia or schizoaffective disorder." | 9.11 | Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. ( Bossie, CA; Greenspan, A; Meyer, JM; Pandina, G; Turkoz, I, 2005) |
| "The purpose of this study was to assess the significance of the hippocampal volume differences and its relation with risperidone treatment in schizophrenia." | 9.10 | Hippocampal volume in schizophrenia and its relationship with risperidone treatment: a stereological study. ( Canan, S; Erbagci, H; Gumusburun, E; Herken, H; Inaloz, S; Savas, HA; Unal, B; Zoroglu, SS, 2002) |
| "To evaluate the efficacy and safety of risperidone in children and adults with Tourette syndrome." | 9.10 | A placebo-controlled trial of risperidone in Tourette syndrome. ( Katsovich, L; Leckman, JF; Peterson, BS; Scahill, L; Schultz, RT, 2003) |
| "The results suggest that lower initial body weight, younger age, undifferentiated subtype, higher dosage, and treatment response (for positive, negative, and cognitive symptoms and social functioning) are associated with greater weight gain in acutely ill patients treated with risperidone." | 9.10 | Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. ( Chang, WH; Chang, YC; Cheng, YC; Lane, HY; Lin, XR; Liu, GC, 2003) |
| "The primary objective of this study was to evaluate insulin sensitivity in healthy subjects treated with olanzapine or risperidone." | 9.10 | Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. ( Breier, A; Carlson, C; Cavazzoni, P; Chinnapongse, S; Dananberg, J; Davis, T; Henry, RR; Mudaliar, S; Mukhopadhyay, N; Ray, A; Sowell, M, 2003) |
| "Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia." | 9.09 | Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. ( Bale, R; Bech, P; Fleurot, O; Möller, HJ; Peuskens, J; Rein, W, 1999) |
| "A retrospective study of the Massachusetts General Hospital Bipolar Clinic database was carried out to identify 50 consecutive treatment trials in patients with DSM-IV bipolar disorder type I who had received adjunctive treatment with risperidone, olanzapine, or clozapine, along with standard mood stabilizers." | 9.09 | A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. ( Ghaemi, SN; Guille, C; Sachs, GS, 2000) |
| "Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses." | 9.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| " The present study examined the hypothesis that schizophrenia itself but not risperidone, an extensively employed SGA, is accountable for metabolic abnormalities." | 8.31 | Effects of Early Risperidone Treatment on Metabolic Parameters in Socially Isolated Rats-Implication of Antipsychotic Intervention across Developmental Stages of Schizophrenia. ( Hsieh, PS; Lin, CC; Liu, YP; Tzeng, NS; Yang, YY, 2023) |
| "This study aimed to assess weight changes following antipsychotic treatment in first-episode schizophrenia (FES) patients and make a comparison of aripiprazole, risperidone and olanzapine." | 8.31 | Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China. ( Cheng, Z; Gao, T; Huang, B; Huang, Z; Pu, C; Shi, C; Yu, X; Zhang, D; Zheng, Y; Zhou, E; Zhou, T, 2023) |
| "A retrospective self-controlled study was conducted on 90 patients with schizophrenia from a single-center treated with olanzapine or clozapine monotherapy, or combined with aripiprazole or ziprasidone which has a small metabolic impact." | 8.02 | The effect of prohibiting outside food during COVID-19 pandemic on the body weight of schizophrenic patients taking olanzapine or clozapine: a retrospective self-controlled study. ( Ding, W; Hu, C; Hu, M; Li, H; Sun, X; Wang, Q; Wang, X; Wu, M; Zhang, C, 2021) |
| "Many patients taking risperidone for the treatment of psychiatric disorders experience substantial body weight gain." | 7.96 | Risperidone stimulates food intake and induces body weight gain via the hypothalamic arcuate nucleus 5-HT2c receptor-NPY pathway. ( Huang, XF; Lin, S; Shi, YC; Wan, XQ; Wang, L; Yang, HQ; Zeng, F; Zhang, ZH, 2020) |
| " After 24-week risperidone treatment, there were significant increases in body weight, BMI, fasting blood-glucose, triglycerides, LDL, hs-CRP, SOD and HOMA-IR (p < 0." | 7.88 | Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia. ( Fan, X; Hei, G; Huang, XF; Kumar, BU; Li, X; Liu, Y; Lv, L; Song, X; Wang, Y; Yuan, X; Zhang, P, 2018) |
| "To analyze weight gain, metabolic hormones, and homocysteine (Hcys) levels in children and adolescents on antipsychotics (AP) during a year-long follow-up." | 7.85 | The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study. ( Arango, C; Baeza, I; Calvo-Escalona, R; Castro-Fornieles, J; de la Serna, E; Merchán-Naranjo, J; Rodríguez-Latorre, P; Vigo, L, 2017) |
| " Throughout the whole clinical course mentioned above, he was under treatment for schizophrenia with drugs including risperidone which possibly affects glucose metabolism." | 7.76 | The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. ( Tsutsumi, E; Yamaguchi, K, 2010) |
| "To compare clinical responses of patients with pediatric bipolar disorder being treated with risperidone versus divalproex." | 7.74 | Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder. ( Gonzalez-Heydrich, JM; Korndörfer, SR; MacMillan, CM; Mrakotsky, C; Tilley, CA; Withney, JE, 2008) |
| "Risperidone has been shown to be clinically effective for the treatment of aggressive behavior in children, yet until recently no information was available regarding whether risperidone exhibits aggression-specific suppression in preclinical studies employing validated developmentally immature animal models of escalated aggression." | 7.74 | Repeated risperidone administration during puberty prevents the generation of the aggressive phenotype in a developmentally immature animal model of escalated aggression. ( Connor, DF; Melloni, RH; Morrison, RL; Ricci, LA; Schwartzer, JJ, 2008) |
| "Risperidone, olanzapine, and clozapine are three atypical antipsychotic medications commonly used in the management of chronic schizophrenia." | 7.73 | Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. ( Gonen, N; Kupchik, M; Mester, R; Roitman, S; Schwartz, S; Spivak, B; Strous, RD; Weizman, A, 2006) |
| "Obesity is highly prevalent among patients treated with atypical antipsychotics for schizophrenia." | 6.73 | Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. ( Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S, 2007) |
| "Only risperidone-treated patients exhibited significant decreases in uncontrolled hostility/excitement and anxiety and depression." | 6.72 | Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. ( Borisov, A; Feldman, J; May, R; Miller, AH; Nemeroff, CB; Rosenberg, J; Savage, R; Tucker, M; Wang, X; Woolwine, B, 2006) |
| "Treatment-emergent adverse events (AEs) were monitored during an 8-week, double-blind, placebo-controlled trial of risperidone (0." | 6.71 | Acute and long-term safety and tolerability of risperidone in children with autism. ( Aman, MG; Arnold, LE; Chuang, S; Davies, M; Ghuman, JK; Gonzalez, NM; Koenig, K; Lindsay, RL; Martin, A; McCracken, JT; McDougle, CJ; McGough, J; Nash, PL; Posey, DJ; Ritz, L; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B, 2005) |
| "Risperidone has also been reported to be useful in the longer-term treatment of bipolar disorder." | 6.43 | Risperidone for bipolar disorders. ( Aulakh, L; Fuller, MA; Keaton, DB; Madhusoodanan, S; Sajatovic, M, 2005) |
| " In conclusion, long-term administration of risperidone may exacerbate diabetes syndrome, nonalcoholic fatty liver disease, and kidney injury." | 5.62 | Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice. ( Chang, CC; Chang, GR; Chou, LS; Hou, PH; Hsiao, LW; Liao, HJ; Lin, TC; Mao, FC; Tsai, HP; Wu, CF; Yang, WC, 2021) |
| "Body weight gain was observed with both the drugs, although a sex-related differential response was noted." | 5.36 | Effect of lactational exposure of olanzapine on body weight of mice: a comparative study on neonates of both the sexes during post-natal development. ( Mishra, AC; Mohanty, B, 2010) |
| "Sibutramine is a serotonin and norepinephrine reuptake intake inhibitor approved for the management of obesity." | 5.35 | Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation. ( Lee, J; Lee, TS; Teoh, T, 2008) |
| "Average weight gain was significantly higher for the olanzapine group (mean = 4." | 5.34 | Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. ( Fleischhaker, C; Heiser, P; Hennighausen, K; Herpertz-Dahlmann, B; Holtkamp, K; Mehler-Wex, C; Rauh, R; Remschmidt, H; Schulz, E; Warnke, A, 2007) |
| "Aripiprazole and risperidone are the only FDA approved medications for treating irritability in autistic disorder, however there are no head-to-head data comparing these agents." | 5.19 | A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. ( Berk, M; Ghanizadeh, A; Sahraeizadeh, A, 2014) |
| "The present study aimed to examine the changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia." | 5.19 | Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia. ( Fan, X; Gao, J; Harrington, A; Li, X; Lv, L; Song, X; Zhang, W; Zhao, J; Ziedonis, D, 2014) |
| " Our research group is developing a non-commercial, multicentric and open label study on the differential efficacy between clozapine and risperidone in first-episode schizophrenia." | 5.17 | Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year. ( Aragües, M; Del Alamo, C; Molina, V; Ovejero, S; Palomo, T; Sanz-Fuentenebro, J; Taboada, D, 2013) |
| "Olanzapine and other second generation antipsychotics have been associated with weight gain, which may be related to changes in appetite and food intake." | 5.16 | Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients. ( Davis, JM; Dwivedi, S; Rachakonda, S; Smith, RC, 2012) |
| "The purpose of this study is to compare the efficacy of olanzapine and risperidone for the acute treatment of first-episode schizophrenia patients with cannabis use disorders." | 5.15 | Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. ( Kane, J; McCormack, J; Miller, R; Napolitano, B; Robinson, DG; Sevy, S; Sunday, S, 2011) |
| "This study aimed to characterize weight changes in schizophrenia patients taking risperidone as part of a randomized, controlled, open-label clinical trial." | 5.15 | Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia. ( Bo, QJ; Chiu, HF; Dixon, LB; Kreyenbuhl, JA; Lai, KY; Lee, EH; Ungvari, GS; Wang, CY; Xiang, YT, 2011) |
| "Patients with schizophrenia or schizoaffective disorder with a body mass index ≥ 27 and non-high-density lipoprotein (non-HDL) cholesterol ≥ 130 mg/dl who were on a stable treatment dosage of olanzapine, quetiapine, or risperidone were randomly assigned to switch to ari-piprazole (N=109) for 24 weeks or stay on their current medication (N=106)." | 5.15 | A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). ( Hamer, RH; LaVange, LM; Lieberman, JA; McEvoy, JP; Nussbaum, AM; Perkins, DO; Ring, KD; Rosenheck, RA; Stroup, TS; Swartz, MS, 2011) |
| "The purpose of this double-blind, placebo-controlled exploratory pilot study was to evaluate the safety and efficacy of risperidone for the treatment of anorexia nervosa." | 5.15 | A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. ( Dodge, M; Ellert, S; Frank, G; Gardner, R; Gralla, J; Hagman, J; O'Lonergan, T; Sigel, E; Wamboldt, MZ, 2011) |
| "Eight patients with psychotic disorders (ages 11-17) who had started risperidone (mean: 1." | 5.14 | Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. ( Maayan, LA; Vakhrusheva, J, 2010) |
| "The current study evaluated the efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia." | 5.13 | Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. ( Casey, DE; Heisterberg, J; Sands, EE; Yang, HM, 2008) |
| "We performed a 6-month, randomized, double-blind study to evaluate the effects of risperidone and olanzapine in patients with schizophrenia." | 5.13 | Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. ( Ader, M; Bergman, RN; Berry, SA; Garvey, WT; Gharabawi, G; Greenspan, A; Mahmoud, R; Mao, L; Morein, J; Musselman, DL; Nemeroff, CB; Phillips, LS; Zhu, Y, 2008) |
| " We examined changes in weight and weight-related quality of life among community patients with schizophrenia treated with aripiprazole (ARI) versus standard of care (SOC), consisting of other marketed atypical antipsychotics (olanzapine, quetiapine, and risperidone)." | 5.13 | Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. ( Corey-Lisle, PK; Crosby, RD; Kan, HJ; Kolotkin, RL; McQuade, RD, 2008) |
| "This open-label, prospective, 4-month study in hyperprolactinemic patients with schizophrenia explored whether prolactin levels decrease after switching antipsychotic therapy to olanzapine." | 5.12 | Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. ( Ahl, J; Kinon, BJ; Liu-Seifert, H; Maguire, GA, 2006) |
| "Among this group of patients with chronic schizophrenia who had just discontinued treatment with an atypical antipsychotic, risperidone and olanzapine were more effective than quetiapine and ziprasidone as reflected by longer time until discontinuation for any reason." | 5.12 | Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. ( Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS, 2006) |
| "Subjects were patients with schizophrenia or schizoaffective disorder enrolled in extension studies (Study A and Study B) after participating in 12-week studies of long-acting injectable risperidone [Kane, J." | 5.12 | Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. ( Eerdekens, M; Khan, A; Kushner, S; Lindenmayer, JP; Van Hove, I, 2007) |
| "Risperidone may be effective in improving tantrums, aggression, or self-injurious behaviour in children with autism, but often leads to weight gain." | 5.12 | Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study. ( Aman, MG; Bozzolo, D; Eugene Arnold, L; Lindsay, RL; McCracken, JT; McDougle, CJ; Pachler, M; Posey, DJ; Scahill, L; Tierney, E; Vitiello, B, 2006) |
| "This subgroup analysis of symptomatically stable patients with schizophrenia or other psychotic disorders in the StoRMi trial determined the efficacy and tolerability of risperidone long-acting injectable in patients changed from oral risperidone monotherapy." | 5.12 | Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. ( Kahn, JP; Medori, R; Sacchetti, E; Schmauss, M, 2007) |
| "The data for this study represent a subset of data from a randomized, double-blinded trial that evaluated subjects with schizophrenia who demonstrated a poor treatment response to clozapine." | 5.12 | Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. ( Barr, AM; Birmingham, CL; Chen, EY; Honer, WG; Macewan, GW; Pomarol-Clotet, E; Procyshyn, RM; Stip, E; Thornton, AE; Wasan, KM; Williams, R, 2007) |
| "Weight change was measured for 63 children and adolescents with autism treated with risperidone for 6 months." | 5.11 | Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. ( Aman, M; Anderson, GM; Arnold, LE; Chuang, S; Martin, A; McCracken, J; McDougle, CJ; Scahill, L; Tierney, E; Vitiello, B, 2004) |
| "These pilot data, from the first prospective comparison study of risperidone and olanzapine in bipolar disorder, suggest that adjunctive administration of either agent may reduce depressive symptom severity." | 5.11 | The antidepressant effects of risperidone and olanzapine in bipolar disorder. ( Kennedy, SH; Konarski, JZ; Mancini, DA; McCann, S; McIntyre, RS; Srinivasan, J, 2004) |
| "The efficacy and tolerability of risperidone long-acting injectable were investigated in patients with schizophrenia or other psychotic disorders who had previously been symptomatically stable on olanzapine treatment." | 5.11 | Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. ( Frazzingaro, S; Gastpar, M; Latif, MA; Lombertie, ER; Masiak, M; Medori, R, 2005) |
| "The aim of this article was to examine the effects of switching from the antipsychotic olanzapine to risperidone on the prevalence of the metabolic syndrome in high-risk overweight or obese patients with schizophrenia or schizoaffective disorder." | 5.11 | Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. ( Bossie, CA; Greenspan, A; Meyer, JM; Pandina, G; Turkoz, I, 2005) |
| "The purpose of this study was to assess the significance of the hippocampal volume differences and its relation with risperidone treatment in schizophrenia." | 5.10 | Hippocampal volume in schizophrenia and its relationship with risperidone treatment: a stereological study. ( Canan, S; Erbagci, H; Gumusburun, E; Herken, H; Inaloz, S; Savas, HA; Unal, B; Zoroglu, SS, 2002) |
| "To evaluate the efficacy and safety of risperidone in children and adults with Tourette syndrome." | 5.10 | A placebo-controlled trial of risperidone in Tourette syndrome. ( Katsovich, L; Leckman, JF; Peterson, BS; Scahill, L; Schultz, RT, 2003) |
| "The results suggest that lower initial body weight, younger age, undifferentiated subtype, higher dosage, and treatment response (for positive, negative, and cognitive symptoms and social functioning) are associated with greater weight gain in acutely ill patients treated with risperidone." | 5.10 | Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. ( Chang, WH; Chang, YC; Cheng, YC; Lane, HY; Lin, XR; Liu, GC, 2003) |
| "The primary objective of this study was to evaluate insulin sensitivity in healthy subjects treated with olanzapine or risperidone." | 5.10 | Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. ( Breier, A; Carlson, C; Cavazzoni, P; Chinnapongse, S; Dananberg, J; Davis, T; Henry, RR; Mudaliar, S; Mukhopadhyay, N; Ray, A; Sowell, M, 2003) |
| "Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia." | 5.09 | Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. ( Bale, R; Bech, P; Fleurot, O; Möller, HJ; Peuskens, J; Rein, W, 1999) |
| "A retrospective study of the Massachusetts General Hospital Bipolar Clinic database was carried out to identify 50 consecutive treatment trials in patients with DSM-IV bipolar disorder type I who had received adjunctive treatment with risperidone, olanzapine, or clozapine, along with standard mood stabilizers." | 5.09 | A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. ( Ghaemi, SN; Guille, C; Sachs, GS, 2000) |
| "Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses." | 5.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| " The present study examined the hypothesis that schizophrenia itself but not risperidone, an extensively employed SGA, is accountable for metabolic abnormalities." | 4.31 | Effects of Early Risperidone Treatment on Metabolic Parameters in Socially Isolated Rats-Implication of Antipsychotic Intervention across Developmental Stages of Schizophrenia. ( Hsieh, PS; Lin, CC; Liu, YP; Tzeng, NS; Yang, YY, 2023) |
| "This study aimed to assess weight changes following antipsychotic treatment in first-episode schizophrenia (FES) patients and make a comparison of aripiprazole, risperidone and olanzapine." | 4.31 | Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China. ( Cheng, Z; Gao, T; Huang, B; Huang, Z; Pu, C; Shi, C; Yu, X; Zhang, D; Zheng, Y; Zhou, E; Zhou, T, 2023) |
| "A retrospective self-controlled study was conducted on 90 patients with schizophrenia from a single-center treated with olanzapine or clozapine monotherapy, or combined with aripiprazole or ziprasidone which has a small metabolic impact." | 4.02 | The effect of prohibiting outside food during COVID-19 pandemic on the body weight of schizophrenic patients taking olanzapine or clozapine: a retrospective self-controlled study. ( Ding, W; Hu, C; Hu, M; Li, H; Sun, X; Wang, Q; Wang, X; Wu, M; Zhang, C, 2021) |
| " Olanzapine treatment was associated with the highest change in weight, with higher doses resulting in more weight gain." | 3.96 | Effects of long-term antipsychotics treatment on body weight: A population-based cohort study. ( Bazo-Alvarez, JC; Carpenter, JR; Hayes, JF; Morris, TP; Petersen, I, 2020) |
| "Many patients taking risperidone for the treatment of psychiatric disorders experience substantial body weight gain." | 3.96 | Risperidone stimulates food intake and induces body weight gain via the hypothalamic arcuate nucleus 5-HT2c receptor-NPY pathway. ( Huang, XF; Lin, S; Shi, YC; Wan, XQ; Wang, L; Yang, HQ; Zeng, F; Zhang, ZH, 2020) |
| "The present study aimed to investigate the effect of bezafibrate on glucolipid abnormalities induced by antipsychotics in schizophrenia." | 3.91 | The effect of bezafibrate in preventing glucolipid abnormalities induced by the antipsychotic risperidone. ( Wei, XY; Yang, YJ; Zhu, XH, 2019) |
| "Children were at risk of weight gain more than adolescents, for both risperidone and, of note, aripiprazole." | 3.91 | Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting. ( Bernardini, R; Biganzoli, E; Bravaccio, C; Capuano, A; Carnovale, C; Clementi, E; Marano, G; Molteni, M; Nobile, M; Pisano, S; Pozzi, M; Radice, S; Rafaniello, C; Rizzo, R; Rossi, F, 2019) |
| " After 24-week risperidone treatment, there were significant increases in body weight, BMI, fasting blood-glucose, triglycerides, LDL, hs-CRP, SOD and HOMA-IR (p < 0." | 3.88 | Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia. ( Fan, X; Hei, G; Huang, XF; Kumar, BU; Li, X; Liu, Y; Lv, L; Song, X; Wang, Y; Yuan, X; Zhang, P, 2018) |
| " However, after accounting for baseline weight, age, sex and diagnosis, olanzapine is still associated with greater weight gain over two years than risperidone or quetiapine." | 3.88 | Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database. ( Beckley, N; Hayes, J; Nazareth, I; Osborn, DP; Petersen, I; Walters, K, 2018) |
| "To analyze weight gain, metabolic hormones, and homocysteine (Hcys) levels in children and adolescents on antipsychotics (AP) during a year-long follow-up." | 3.85 | The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study. ( Arango, C; Baeza, I; Calvo-Escalona, R; Castro-Fornieles, J; de la Serna, E; Merchán-Naranjo, J; Rodríguez-Latorre, P; Vigo, L, 2017) |
| " After 4-week administration, clozapine (10mg/kg/d) and risperidone (1mg/kg/d) both caused glucose intolerance and insulin resistance in VD deficient rats, but not in rats with sufficient VD status." | 3.81 | Vitamin D deficiency exacerbates atypical antipsychotic-induced metabolic side effects in rats: involvement of the INSIG/SREBP pathway. ( Cai, H; Dang, R; Guo, R; He, X; Jiang, P; Li, H; Liu, Y; Wu, Y; Xu, P; Zhang, L; Zhu, W, 2015) |
| " To dissect the role of the dopamine D2 receptor (D2R), an important receptor in the pharmacology of antipsychotic drugs, we analyzed the effect of olanzapine, risperidone, and ziprasidone on changes in body weight and food intake in male wild-type (WT) and D2R knockout (D2R(-/-)) mice." | 3.76 | Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice. ( Baik, JH; Choi, SY; Noh, JS; Yoon, S, 2010) |
| " Throughout the whole clinical course mentioned above, he was under treatment for schizophrenia with drugs including risperidone which possibly affects glucose metabolism." | 3.76 | The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. ( Tsutsumi, E; Yamaguchi, K, 2010) |
| "Risperidone is a promising agent for the treatment of schizophrenia, Tourette's disorder, mood disorders, and disruptive behavior disorders in young populations." | 3.76 | Six months of treatment with risperidone may be associated with nonsignificant abnormalities of liver function tests in children and adolescents: a longitudinal, observational study from Turkey. ( Erdogan, A; Karaman, MG; Kurcer, MA; Ozdemir, E; Tufan, AE; Yurteri, N, 2010) |
| "To compare clinical responses of patients with pediatric bipolar disorder being treated with risperidone versus divalproex." | 3.74 | Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder. ( Gonzalez-Heydrich, JM; Korndörfer, SR; MacMillan, CM; Mrakotsky, C; Tilley, CA; Withney, JE, 2008) |
| "Risperidone has been shown to be clinically effective for the treatment of aggressive behavior in children, yet until recently no information was available regarding whether risperidone exhibits aggression-specific suppression in preclinical studies employing validated developmentally immature animal models of escalated aggression." | 3.74 | Repeated risperidone administration during puberty prevents the generation of the aggressive phenotype in a developmentally immature animal model of escalated aggression. ( Connor, DF; Melloni, RH; Morrison, RL; Ricci, LA; Schwartzer, JJ, 2008) |
| "5 mg/kg), or vehicle was injected intraperitoneally once daily for 22 days; food selection, water intake, and body weight were recorded daily, while body composition and plasma hormones (insulin, glucose, nonesterified free fatty acid, total cholesterol, glycerol, triacylglycerol, leptin, and prolactin) were analyzed at the end of the study." | 3.74 | The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. ( Anjum, N; Cheetham, S; Dickinson, K; Fell, MJ; Marshall, KM; Neill, JC; Peltola, LM; Vickers, S, 2007) |
| "Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects." | 3.73 | Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. ( Allison, DB; Anderson, EJ; Borba, CP; Cagliero, E; Copeland, PM; Daley, TB; Evins, AE; Goff, DC; Hayden, D; Henderson, DC; Schoenfeld, D; Weber, MT, 2005) |
| " We examined the effects of atypical antipsychotics olanzapine (OLZ) and risperidone (RIS) versus placebo on adiposity, insulin sensitivity (S(I)), and pancreatic beta-cell compensation." | 3.73 | Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. ( Ader, M; Bergman, RN; Catalano, KJ; Hucking, K; Ionut, V; Kabir, M; Kim, SP; Richey, JM, 2005) |
| "This study confirms that elevated levels of triglyceride and body weight could be associated with the use of olanzapine as compared with risperidone." | 3.73 | A crossover study on lipid and weight changes associated with olanzapine and risperidone. ( Pariante, CM; Su, KP; Wu, PL, 2005) |
| "Risperidone, olanzapine, and clozapine are three atypical antipsychotic medications commonly used in the management of chronic schizophrenia." | 3.73 | Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. ( Gonen, N; Kupchik, M; Mester, R; Roitman, S; Schwartz, S; Spivak, B; Strous, RD; Weizman, A, 2006) |
| " To investigate the possible mechanisms of antipsychotic-induced metabolic effects, we studied the impact of chronic administration of a typical antipsychotic drug (haloperidol) and an atypical antipsychotic (risperidone) to male rats on food intake, body weight, adiposity, and the circulating concentrations of hormones and metabolites that can influence energy homeostasis." | 3.73 | Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. ( Dedova, I; Duffy, L; Herzog, H; Karl, T; Lee, NJ; Lin, EJ; Matsumoto, I; O'brien, E; Sainsbury, A; Slack, K, 2006) |
| "Previous studies showed that the antipsychotic drugs (APDs) sulpiride (SUL) and risperidone (RIS) induced body weight gain (BWG), hyperphagia, and increased serum levels of leptin, prolactin and corticosterone in female rats." | 3.72 | Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. ( Baptista, T; Beaulieu, S; de Baptista, EA; Joober, R; Kin, NM; Lalonde, J; Plamondon, J; Richard, D, 2004) |
| "Risperidone was shown to have significant anti-manic effects which was observed as early as week 1, following start of treatment." | 2.77 | Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania. ( Hsu, MC; Kuo, CC; Ouyang, WC; Yeh, IN, 2012) |
| "Obesity is highly prevalent among patients treated with atypical antipsychotics for schizophrenia." | 2.73 | Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. ( Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S, 2007) |
| "Risperidone dosage was based on weight (patients <50 kg: 0." | 2.72 | A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. ( Augustyns, I; Buitelaar, J; Eerdekens, M; Reyes, M; Toren, P, 2006) |
| "Only risperidone-treated patients exhibited significant decreases in uncontrolled hostility/excitement and anxiety and depression." | 2.72 | Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. ( Borisov, A; Feldman, J; May, R; Miller, AH; Nemeroff, CB; Rosenberg, J; Savage, R; Tucker, M; Wang, X; Woolwine, B, 2006) |
| "Risperidone-treated patients had clinically and statistically significant reductions in both disruptive behavior and hyperactivity subscale scores, compared to placebo, regardless of concomitant stimulant use." | 2.71 | Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. ( Aman, MG; Binder, C; Turgay, A, 2004) |
| "Patients aged > or = 18 years with schizoaffective disorder (DSM-IV), who required a change of medication, received risperidone long-acting injectable 25 mg (increased to 37." | 2.71 | Long-acting risperidone in stable patients with schizoaffective disorder. ( Benoit, M; Bräunig, P; Lex, A; Medori, R; Mohl, A; Opjordsmoen, S; Schreiner, A; Westlye, K, 2005) |
| "Treatment-emergent adverse events (AEs) were monitored during an 8-week, double-blind, placebo-controlled trial of risperidone (0." | 2.71 | Acute and long-term safety and tolerability of risperidone in children with autism. ( Aman, MG; Arnold, LE; Chuang, S; Davies, M; Ghuman, JK; Gonzalez, NM; Koenig, K; Lindsay, RL; Martin, A; McCracken, JT; McDougle, CJ; McGough, J; Nash, PL; Posey, DJ; Ritz, L; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B, 2005) |
| "Risperidone has also been reported to be useful in the longer-term treatment of bipolar disorder." | 2.43 | Risperidone for bipolar disorders. ( Aulakh, L; Fuller, MA; Keaton, DB; Madhusoodanan, S; Sajatovic, M, 2005) |
| " In conclusion, long-term administration of risperidone may exacerbate diabetes syndrome, nonalcoholic fatty liver disease, and kidney injury." | 1.62 | Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice. ( Chang, CC; Chang, GR; Chou, LS; Hou, PH; Hsiao, LW; Liao, HJ; Lin, TC; Mao, FC; Tsai, HP; Wu, CF; Yang, WC, 2021) |
| "Olanzapine (6 mg/kg) treatment significantly altered glucose and lipid homeostasis which was further accompanied by elevated levels of proinflammatory cytokines, ghrelin and leptin." | 1.51 | Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor. ( Bansal, Y; Kuhad, A; Medhi, B; Saroj, P; Singh, R; Sodhi, RK, 2019) |
| " The results indicated that the dosage of 10-90 mg/kg of RM for 2 weeks did not cause treatment-related mortality." | 1.42 | A 12-week subchronic intramuscular toxicity study of risperidone-loaded microspheres in rats. ( Cen, X; Dong, Q; Du, G; Fu, F; Guan, X; Tian, J; Wang, W; Ye, L; Yu, X; Zhang, J; Zhu, X, 2015) |
| " At the end of recovery phase, the above changes mostly recovered to normal, and on administering 3 mg/kg dose level once in 2 weeks on Beagle dogs showed no observed adverse effect." | 1.40 | A 12-week intramuscular toxicity study of risperidone-loaded microspheres in Beagle dogs. ( Cen, X; Du, G; Guan, X; Li, Y; Liu, W; Tian, J; Wang, W; Ye, L; Yu, P; Zhang, J, 2014) |
| "Body weight gain was observed with both the drugs, although a sex-related differential response was noted." | 1.36 | Effect of lactational exposure of olanzapine on body weight of mice: a comparative study on neonates of both the sexes during post-natal development. ( Mishra, AC; Mohanty, B, 2010) |
| "Body weight was measured daily, skeletal dimension monthly, and bone mineralization and hormones bimonthly." | 1.36 | Some effects of risperidone and quetiapine on growth parameters and hormone levels in young pigtail macaques. ( Crouthamel, B; Sackett, G; Unis, A, 2010) |
| "To characterize pharmacokinetic (PK) variability of risperidone and 9-OH risperidone using sparse sampling and to evaluate the effect of covariates on PK parameters." | 1.35 | Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. ( Aravagiri, M; Bies, RR; Coley, K; Feng, Y; Kirshner, M; Marder, S; Miller, D; Pollock, BG; Schneider, L, 2008) |
| "Antipsychotic treatment during pregnancy is indicated when risk of drug exposure to the fetus is outweighed by the untreated psychosis in the mother." | 1.35 | Distinct neurobehavioral consequences of prenatal exposure to sulpiride (SUL) and risperidone (RIS) in rats. ( Hao, Y; Liu, H; Liu, Z; Lu, XH; Ouyang, X; Xu, L; Zuo, J, 2008) |
| "Sibutramine is a serotonin and norepinephrine reuptake intake inhibitor approved for the management of obesity." | 1.35 | Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation. ( Lee, J; Lee, TS; Teoh, T, 2008) |
| "Average weight gain was significantly higher for the olanzapine group (mean = 4." | 1.34 | Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. ( Fleischhaker, C; Heiser, P; Hennighausen, K; Herpertz-Dahlmann, B; Holtkamp, K; Mehler-Wex, C; Rauh, R; Remschmidt, H; Schulz, E; Warnke, A, 2007) |
| " The present study compares the effect of chronic administration of typical and atypical antipsychotics on neurochemical profile in rat forebrain." | 1.34 | Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia. ( Bishnoi, M; Chopra, K; Kulkarni, SK; Kumar, A, 2007) |
| " Future prospective studies are necessary to clarify whether the prescribed dosage should be different in young and older patients." | 1.34 | Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. ( Aichhorn, W; Hinterhuber, H; Kemmler, G; Marksteiner, J; Stuppaeck, C; Walch, T; Zernig, G, 2007) |
| " Mice were acclimated to individual housing, given ad libitum access to chow and water, dosed with placebo peanut butter pills for 1 week, and then dosed daily with AAPD-laced peanut butter pills for 4 weeks." | 1.33 | Antipsychotic drug-induced weight gain: development of an animal model. ( Allison, DB; Casey, DE; Cope, MB; Fernández, JR; Geary, N; Nagy, TR, 2005) |
| "Atypical antipsychotics successfully treat schizophrenia and other conditions, with a lower incidence of extrapyramidal side effects than other agents used in treatment of these disorders." | 1.32 | Weight change after an atypical antipsychotic switch. ( Acholonu, WW; Bengtson, MA; Renner, BT; Ried, LD; Wilcox, BM, 2003) |
| " Chronic administration of these drugs, however, altered BDNF synthesis or release and expression of TrkB-immunoreactivity within the brain." | 1.31 | Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. ( Aloe, L; Angelucci, F; Mathé, AA, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.92) | 18.2507 |
| 2000's | 65 (59.63) | 29.6817 |
| 2010's | 37 (33.94) | 24.3611 |
| 2020's | 6 (5.50) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, X | 1 |
| Zhang, Y | 1 |
| Chen, Y | 1 |
| Qiu, Y | 1 |
| Yu, M | 1 |
| Xu, X | 1 |
| Liu, X | 1 |
| Liu, BF | 1 |
| Zhang, L | 2 |
| Zhang, G | 1 |
| Tzeng, NS | 1 |
| Yang, YY | 1 |
| Lin, CC | 1 |
| Hsieh, PS | 1 |
| Liu, YP | 1 |
| Zhou, T | 1 |
| Pu, C | 1 |
| Huang, Z | 1 |
| Gao, T | 1 |
| Zhou, E | 1 |
| Zheng, Y | 1 |
| Zhang, D | 1 |
| Huang, B | 1 |
| Cheng, Z | 1 |
| Shi, C | 1 |
| Yu, X | 2 |
| Wei, XY | 1 |
| Yang, YJ | 1 |
| Zhu, XH | 1 |
| Bazo-Alvarez, JC | 1 |
| Morris, TP | 1 |
| Carpenter, JR | 1 |
| Hayes, JF | 1 |
| Petersen, I | 2 |
| Wan, XQ | 1 |
| Zeng, F | 1 |
| Huang, XF | 2 |
| Yang, HQ | 1 |
| Wang, L | 1 |
| Shi, YC | 1 |
| Zhang, ZH | 1 |
| Lin, S | 1 |
| Tsai, HP | 1 |
| Hou, PH | 1 |
| Mao, FC | 1 |
| Chang, CC | 1 |
| Yang, WC | 1 |
| Wu, CF | 1 |
| Liao, HJ | 1 |
| Lin, TC | 1 |
| Chou, LS | 1 |
| Hsiao, LW | 1 |
| Chang, GR | 1 |
| Zhang, C | 1 |
| Wang, X | 2 |
| Hu, C | 1 |
| Ding, W | 1 |
| Li, H | 2 |
| Wu, M | 1 |
| Hu, M | 1 |
| Wang, Q | 1 |
| Sun, X | 1 |
| Yuan, X | 1 |
| Zhang, P | 1 |
| Wang, Y | 1 |
| Liu, Y | 2 |
| Li, X | 2 |
| Kumar, BU | 1 |
| Hei, G | 1 |
| Lv, L | 2 |
| Fan, X | 2 |
| Song, X | 2 |
| Osborn, DP | 1 |
| Beckley, N | 1 |
| Walters, K | 1 |
| Nazareth, I | 1 |
| Hayes, J | 1 |
| Pozzi, M | 1 |
| Pisano, S | 1 |
| Marano, G | 1 |
| Carnovale, C | 1 |
| Bravaccio, C | 1 |
| Rafaniello, C | 1 |
| Capuano, A | 1 |
| Rossi, F | 1 |
| Rizzo, R | 1 |
| Bernardini, R | 1 |
| Nobile, M | 1 |
| Molteni, M | 1 |
| Clementi, E | 1 |
| Biganzoli, E | 1 |
| Radice, S | 1 |
| Singh, R | 1 |
| Bansal, Y | 1 |
| Sodhi, RK | 1 |
| Saroj, P | 1 |
| Medhi, B | 1 |
| Kuhad, A | 1 |
| Nurmi, EL | 1 |
| Spilman, SL | 1 |
| Whelan, F | 1 |
| Scahill, LL | 1 |
| Aman, MG | 4 |
| McDougle, CJ | 4 |
| Arnold, LE | 3 |
| Handen, B | 1 |
| Johnson, C | 1 |
| Sukhodolsky, DG | 1 |
| Posey, DJ | 3 |
| Lecavalier, L | 1 |
| Stigler, KA | 1 |
| Ritz, L | 2 |
| Tierney, E | 4 |
| Vitiello, B | 4 |
| McCracken, JT | 3 |
| Ghanizadeh, A | 1 |
| Sahraeizadeh, A | 1 |
| Berk, M | 1 |
| Sanz-Fuentenebro, J | 1 |
| Taboada, D | 1 |
| Palomo, T | 1 |
| Aragües, M | 1 |
| Ovejero, S | 1 |
| Del Alamo, C | 1 |
| Molina, V | 1 |
| Tian, J | 2 |
| Wang, W | 2 |
| Ye, L | 2 |
| Cen, X | 2 |
| Guan, X | 2 |
| Zhang, J | 2 |
| Yu, P | 1 |
| Du, G | 2 |
| Liu, W | 1 |
| Li, Y | 1 |
| Zhang, W | 1 |
| Gao, J | 1 |
| Zhao, J | 1 |
| Harrington, A | 1 |
| Ziedonis, D | 1 |
| Hou, YC | 1 |
| Lai, CH | 1 |
| Zhu, X | 1 |
| Dong, Q | 1 |
| Fu, F | 1 |
| Dang, R | 1 |
| Jiang, P | 1 |
| Cai, H | 1 |
| Guo, R | 1 |
| Wu, Y | 1 |
| Zhu, W | 1 |
| He, X | 1 |
| Xu, P | 1 |
| Ersland, KM | 1 |
| Skrede, S | 1 |
| Røst, TH | 1 |
| Berge, RK | 1 |
| Steen, VM | 1 |
| Baeza, I | 1 |
| Vigo, L | 1 |
| de la Serna, E | 1 |
| Calvo-Escalona, R | 1 |
| Merchán-Naranjo, J | 1 |
| Rodríguez-Latorre, P | 1 |
| Arango, C | 1 |
| Castro-Fornieles, J | 1 |
| Jahangard, L | 1 |
| Akbarian, S | 1 |
| Haghighi, M | 1 |
| Ahmadpanah, M | 1 |
| Keshavarzi, A | 1 |
| Bajoghli, H | 1 |
| Sadeghi Bahmani, D | 1 |
| Holsboer-Trachsler, E | 1 |
| Brand, S | 1 |
| MacMillan, CM | 1 |
| Withney, JE | 1 |
| Korndörfer, SR | 1 |
| Tilley, CA | 1 |
| Mrakotsky, C | 1 |
| Gonzalez-Heydrich, JM | 1 |
| Casey, DE | 2 |
| Sands, EE | 1 |
| Heisterberg, J | 1 |
| Yang, HM | 1 |
| Schwartzer, JJ | 1 |
| Connor, DF | 1 |
| Morrison, RL | 1 |
| Ricci, LA | 1 |
| Melloni, RH | 1 |
| Feng, Y | 1 |
| Pollock, BG | 1 |
| Coley, K | 1 |
| Marder, S | 1 |
| Miller, D | 1 |
| Kirshner, M | 1 |
| Aravagiri, M | 1 |
| Schneider, L | 1 |
| Bies, RR | 1 |
| Gebhardt, S | 2 |
| Haberhausen, M | 2 |
| Heinzel-Gutenbrunner, M | 2 |
| Gebhardt, N | 1 |
| Remschmidt, H | 3 |
| Krieg, JC | 2 |
| Hebebrand, J | 2 |
| Theisen, FM | 2 |
| Weinbrenner, A | 1 |
| Peus, V | 1 |
| Inta, D | 1 |
| Englisch, S | 1 |
| Zink, M | 1 |
| Mishra, AC | 1 |
| Mohanty, B | 1 |
| Degrauw, RS | 1 |
| Li, JZ | 1 |
| Gilbert, DL | 1 |
| Yoon, S | 1 |
| Noh, JS | 1 |
| Choi, SY | 1 |
| Baik, JH | 1 |
| Araki, S | 1 |
| Ohji, T | 1 |
| Shiota, N | 1 |
| Dobashi, K | 1 |
| Shimono, M | 1 |
| Shirahata, A | 1 |
| Maayan, LA | 1 |
| Vakhrusheva, J | 1 |
| Hong, CJ | 1 |
| Liou, YJ | 1 |
| Bai, YM | 1 |
| Chen, TT | 1 |
| Wang, YC | 1 |
| Tsai, SJ | 1 |
| Wehmeier, PM | 1 |
| Kühnau, W | 1 |
| Schmidtke, J | 1 |
| Yamaguchi, K | 1 |
| Tsutsumi, E | 1 |
| Erdogan, A | 2 |
| Karaman, MG | 1 |
| Ozdemir, E | 1 |
| Yurteri, N | 1 |
| Tufan, AE | 1 |
| Kurcer, MA | 1 |
| Lee, SY | 1 |
| Park, MH | 1 |
| Patkar, AA | 1 |
| Pae, CU | 1 |
| Celikyurt, IK | 1 |
| Kayir, H | 1 |
| Ulak, G | 1 |
| Erden, FB | 1 |
| Ulusoy, GK | 1 |
| Uzbay, TI | 1 |
| Sackett, G | 1 |
| Unis, A | 1 |
| Crouthamel, B | 1 |
| Sevy, S | 1 |
| Robinson, DG | 1 |
| Sunday, S | 1 |
| Napolitano, B | 1 |
| Miller, R | 1 |
| McCormack, J | 1 |
| Kane, J | 1 |
| Xiang, YT | 1 |
| Wang, CY | 1 |
| Ungvari, GS | 1 |
| Kreyenbuhl, JA | 1 |
| Chiu, HF | 1 |
| Lai, KY | 1 |
| Lee, EH | 1 |
| Bo, QJ | 1 |
| Dixon, LB | 1 |
| Stroup, TS | 2 |
| McEvoy, JP | 2 |
| Ring, KD | 1 |
| Hamer, RH | 1 |
| LaVange, LM | 1 |
| Swartz, MS | 2 |
| Rosenheck, RA | 2 |
| Perkins, DO | 2 |
| Nussbaum, AM | 1 |
| Lieberman, JA | 2 |
| Hagman, J | 1 |
| Gralla, J | 1 |
| Sigel, E | 1 |
| Ellert, S | 1 |
| Dodge, M | 1 |
| Gardner, R | 1 |
| O'Lonergan, T | 1 |
| Frank, G | 1 |
| Wamboldt, MZ | 1 |
| Demb, H | 1 |
| Valicenti-McDermott, M | 1 |
| Navarro, A | 1 |
| Ayoob, KT | 1 |
| Martínez-Ortega, JM | 1 |
| Diaz-Atienza, F | 1 |
| Gutiérrez-Rojas, L | 1 |
| Jurado, D | 1 |
| Gurpegui, M | 1 |
| Ouyang, WC | 1 |
| Hsu, MC | 1 |
| Yeh, IN | 1 |
| Kuo, CC | 1 |
| Smith, RC | 1 |
| Rachakonda, S | 1 |
| Dwivedi, S | 1 |
| Davis, JM | 1 |
| Schuster, JP | 1 |
| Raucher-Chéné, D | 1 |
| Lemogne, C | 1 |
| Rouillon, F | 1 |
| Gasquet, I | 1 |
| Leguay, D | 1 |
| Gierski, F | 1 |
| Azorin, JM | 1 |
| Limosin, F | 1 |
| Savas, HA | 1 |
| Unal, B | 1 |
| Erbagci, H | 1 |
| Inaloz, S | 1 |
| Herken, H | 1 |
| Canan, S | 1 |
| Gumusburun, E | 1 |
| Zoroglu, SS | 1 |
| Baptista, T | 2 |
| Araujo de Baptista, E | 1 |
| Ying Kin, NM | 1 |
| Beaulieu, S | 2 |
| Walker, D | 1 |
| Joober, R | 2 |
| Lalonde, J | 2 |
| Richard, D | 2 |
| Scahill, L | 4 |
| Leckman, JF | 1 |
| Schultz, RT | 1 |
| Katsovich, L | 1 |
| Peterson, BS | 1 |
| Lane, HY | 1 |
| Chang, YC | 1 |
| Cheng, YC | 1 |
| Liu, GC | 1 |
| Lin, XR | 1 |
| Chang, WH | 1 |
| Ried, LD | 1 |
| Renner, BT | 1 |
| Bengtson, MA | 1 |
| Wilcox, BM | 1 |
| Acholonu, WW | 1 |
| Weiden, PJ | 1 |
| Daniel, DG | 1 |
| Simpson, G | 1 |
| Romano, SJ | 1 |
| Sowell, M | 1 |
| Mukhopadhyay, N | 1 |
| Cavazzoni, P | 1 |
| Carlson, C | 1 |
| Mudaliar, S | 1 |
| Chinnapongse, S | 1 |
| Ray, A | 1 |
| Davis, T | 1 |
| Breier, A | 1 |
| Henry, RR | 1 |
| Dananberg, J | 1 |
| Mosolov, SN | 1 |
| Kabanov, SO | 1 |
| Martin, A | 2 |
| Anderson, GM | 1 |
| Aman, M | 1 |
| McCracken, J | 1 |
| Chuang, S | 2 |
| Binder, C | 1 |
| Turgay, A | 1 |
| McIntyre, RS | 1 |
| Mancini, DA | 1 |
| Srinivasan, J | 1 |
| McCann, S | 1 |
| Konarski, JZ | 1 |
| Kennedy, SH | 1 |
| Scherer, J | 1 |
| Dobmeier, P | 1 |
| Kuhn, K | 1 |
| Schmaus, W | 1 |
| de Baptista, EA | 1 |
| Plamondon, J | 1 |
| Kin, NM | 1 |
| Henderson, DC | 1 |
| Cagliero, E | 1 |
| Copeland, PM | 1 |
| Borba, CP | 1 |
| Evins, AE | 1 |
| Hayden, D | 1 |
| Weber, MT | 1 |
| Anderson, EJ | 1 |
| Allison, DB | 2 |
| Daley, TB | 1 |
| Schoenfeld, D | 1 |
| Goff, DC | 1 |
| Ader, M | 2 |
| Kim, SP | 1 |
| Catalano, KJ | 1 |
| Ionut, V | 1 |
| Hucking, K | 1 |
| Richey, JM | 1 |
| Kabir, M | 1 |
| Bergman, RN | 2 |
| Cope, MB | 1 |
| Nagy, TR | 1 |
| Fernández, JR | 1 |
| Geary, N | 1 |
| Ota, M | 1 |
| Mori, K | 1 |
| Nakashima, A | 1 |
| Kaneko, YS | 1 |
| Takahashi, H | 1 |
| Ota, A | 1 |
| Sajatovic, M | 1 |
| Madhusoodanan, S | 1 |
| Fuller, MA | 1 |
| Aulakh, L | 1 |
| Keaton, DB | 1 |
| Mohl, A | 1 |
| Westlye, K | 1 |
| Opjordsmoen, S | 1 |
| Lex, A | 1 |
| Schreiner, A | 1 |
| Benoit, M | 1 |
| Bräunig, P | 1 |
| Medori, R | 3 |
| Gastpar, M | 1 |
| Masiak, M | 1 |
| Latif, MA | 1 |
| Frazzingaro, S | 1 |
| Lombertie, ER | 1 |
| Lin, YH | 1 |
| Liu, CY | 1 |
| Hsiao, MC | 1 |
| Su, KP | 1 |
| Wu, PL | 1 |
| Pariante, CM | 1 |
| Davies, M | 1 |
| Nash, PL | 1 |
| Shah, B | 1 |
| Gonzalez, NM | 1 |
| Swiezy, NB | 1 |
| Koenig, K | 1 |
| McGough, J | 1 |
| Ghuman, JK | 1 |
| Lindsay, RL | 2 |
| Kinon, BJ | 2 |
| Ahl, J | 1 |
| Liu-Seifert, H | 1 |
| Maguire, GA | 1 |
| Meyer, JM | 2 |
| Pandina, G | 1 |
| Bossie, CA | 1 |
| Turkoz, I | 1 |
| Greenspan, A | 2 |
| Reyes, M | 1 |
| Buitelaar, J | 1 |
| Toren, P | 1 |
| Augustyns, I | 1 |
| Eerdekens, M | 2 |
| Kostulski, A | 1 |
| Wyszogrodzka-Kucharska, A | 1 |
| Rabe-Jabłońska, J | 1 |
| Davis, SM | 1 |
| Keefe, RS | 1 |
| Davis, CE | 1 |
| Severe, J | 1 |
| Hsiao, JK | 1 |
| Savage, R | 1 |
| Borisov, A | 1 |
| Rosenberg, J | 1 |
| Woolwine, B | 1 |
| Tucker, M | 1 |
| May, R | 1 |
| Feldman, J | 1 |
| Nemeroff, CB | 2 |
| Miller, AH | 1 |
| Strous, RD | 1 |
| Kupchik, M | 1 |
| Roitman, S | 1 |
| Schwartz, S | 1 |
| Gonen, N | 1 |
| Mester, R | 1 |
| Weizman, A | 2 |
| Spivak, B | 2 |
| Lin, EJ | 1 |
| Lee, NJ | 1 |
| Slack, K | 1 |
| Karl, T | 1 |
| Duffy, L | 1 |
| O'brien, E | 1 |
| Matsumoto, I | 1 |
| Dedova, I | 1 |
| Herzog, H | 1 |
| Sainsbury, A | 1 |
| Mozes, T | 1 |
| Ebert, T | 1 |
| Michal, SE | 1 |
| Lindenmayer, JP | 1 |
| Khan, A | 1 |
| Van Hove, I | 1 |
| Kushner, S | 1 |
| Fleischhaker, C | 1 |
| Heiser, P | 1 |
| Hennighausen, K | 1 |
| Herpertz-Dahlmann, B | 1 |
| Holtkamp, K | 1 |
| Mehler-Wex, C | 1 |
| Rauh, R | 1 |
| Schulz, E | 1 |
| Warnke, A | 1 |
| Eugene Arnold, L | 1 |
| Pachler, M | 1 |
| Bozzolo, D | 1 |
| Schmauss, M | 1 |
| Sacchetti, E | 1 |
| Kahn, JP | 1 |
| Neovius, M | 1 |
| Eberhard, J | 2 |
| Lindström, E | 2 |
| Levander, S | 2 |
| Holstad, M | 1 |
| Bishnoi, M | 1 |
| Kumar, A | 1 |
| Chopra, K | 1 |
| Kulkarni, SK | 1 |
| Kim, B | 1 |
| Kim, SJ | 1 |
| Son, JI | 1 |
| Joo, YH | 1 |
| Popovic, V | 1 |
| Doknic, M | 1 |
| Maric, N | 1 |
| Pekic, S | 1 |
| Damjanovic, A | 1 |
| Miljic, D | 1 |
| Popovic, S | 1 |
| Miljic, N | 1 |
| Djurovic, M | 1 |
| Jasovic-Gasic, M | 1 |
| Dieguez, C | 1 |
| Casanueva, FF | 1 |
| Fell, MJ | 1 |
| Anjum, N | 1 |
| Dickinson, K | 1 |
| Marshall, KM | 1 |
| Peltola, LM | 1 |
| Vickers, S | 1 |
| Cheetham, S | 1 |
| Neill, JC | 1 |
| Crocq, MA | 1 |
| Guillon, MS | 1 |
| Bailey, PE | 1 |
| Provost, D | 1 |
| Procyshyn, RM | 1 |
| Wasan, KM | 1 |
| Thornton, AE | 1 |
| Barr, AM | 1 |
| Chen, EY | 1 |
| Pomarol-Clotet, E | 1 |
| Stip, E | 1 |
| Williams, R | 1 |
| Macewan, GW | 1 |
| Birmingham, CL | 1 |
| Honer, WG | 1 |
| Zuo, J | 1 |
| Liu, Z | 1 |
| Ouyang, X | 1 |
| Liu, H | 1 |
| Hao, Y | 1 |
| Xu, L | 1 |
| Lu, XH | 1 |
| Aichhorn, W | 1 |
| Marksteiner, J | 1 |
| Walch, T | 1 |
| Zernig, G | 1 |
| Hinterhuber, H | 1 |
| Stuppaeck, C | 1 |
| Kemmler, G | 1 |
| Saddichha, S | 1 |
| Manjunatha, N | 1 |
| Ameen, S | 1 |
| Akhtar, S | 1 |
| Lee, J | 1 |
| Teoh, T | 1 |
| Lee, TS | 1 |
| Ruedrich, SL | 1 |
| Swales, TP | 1 |
| Rossvanes, C | 1 |
| Diana, L | 1 |
| Arkadiev, V | 1 |
| Lim, K | 1 |
| Atasoy, N | 1 |
| Akkurt, H | 1 |
| Ozturk, D | 1 |
| Karaahmet, E | 1 |
| Yalug, I | 1 |
| Yalug, K | 1 |
| Ankarali, H | 1 |
| Balcioglu, I | 1 |
| Garvey, WT | 1 |
| Phillips, LS | 1 |
| Gharabawi, G | 1 |
| Mahmoud, R | 1 |
| Berry, SA | 1 |
| Musselman, DL | 1 |
| Morein, J | 1 |
| Zhu, Y | 1 |
| Mao, L | 1 |
| Kolotkin, RL | 1 |
| Corey-Lisle, PK | 1 |
| Crosby, RD | 1 |
| Kan, HJ | 1 |
| McQuade, RD | 1 |
| Peuskens, J | 1 |
| Bech, P | 1 |
| Möller, HJ | 1 |
| Bale, R | 1 |
| Fleurot, O | 1 |
| Rein, W | 1 |
| Angelucci, F | 1 |
| Mathé, AA | 1 |
| Aloe, L | 1 |
| Guille, C | 1 |
| Sachs, GS | 1 |
| Ghaemi, SN | 1 |
| Bouchard, RH | 1 |
| Demers, MF | 1 |
| Simoneau, I | 1 |
| Alméras, N | 1 |
| Villeneuve, J | 1 |
| Mottard, JP | 1 |
| Cadrin, C | 1 |
| Lemieux, I | 1 |
| Després, JP | 1 |
| Basson, BR | 1 |
| Taylor, CC | 1 |
| Szymanski, KA | 1 |
| Gilmore, JA | 1 |
| Tollefson, GD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Population Pharmacokinetic Modeling of Qishe Pill in Three Major TCM-defined Constitutional Types of Healthy Chinese Subjects: Study Protocol for a Phase I Clinical Trial[NCT02294448] | Phase 1 | 36 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| Clinical Management of Metabolic Problems in Patients With Schizophrenia[NCT00423878] | Phase 4 | 215 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Metformin and Lorcaserin for Weight Loss in Schizophrenia[NCT02796144] | Phase 4 | 71 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to The FDA advised of a possible health risk associated with lorcaserin and the drug is being withdrawn.) | ||
| A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa[NCT00140426] | Phase 4 | 41 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Independent Investigator Grant Study-Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism[NCT00287820] | Phase 4 | 46 participants (Anticipated) | Interventional | 2004-02-29 | Completed | ||
| Association of the Amisulpride Treatment Response in Patients With Schizophrenia With the Findings of Brain Structural Magnetic Resonance Imaging[NCT02095938] | Phase 4 | 20 participants (Actual) | Interventional | 2014-01-31 | Enrolling by invitation | ||
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588] | Phase 4 | 60 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Placebo-Controlled Study of Risperidone for the Treatment of Children and Adolescents With Autism and Negative Behavioral Symptoms[NCT00005014] | Phase 3 | 101 participants (Actual) | Interventional | 1997-10-31 | Completed | ||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)[NCT00014001] | Phase 4 | 1,600 participants | Interventional | 2000-12-31 | Completed | ||
| Metabolic Profile and Anthropometric Changes in Schizophrenia[NCT00534183] | 2,006 participants (Actual) | Interventional | 2006-06-30 | Completed | |||
| Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain[NCT01043250] | 81 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in non-HDL cholesterol measured at baseline and every 4 weeks for 24 weeks. The efficacy analysis corresponded to a comparison of change in non-HDL cholesterol from baseline to 24 weeks between treatment groups (stay versus switch). Repeated measurements mixed effects linear models were fit for the primary analysis. (NCT00423878)
Timeframe: 24 weeks
| Intervention | mg/dL non-HDL cholesterol (Least Squares Mean) |
|---|---|
| Switch Group | -20.2 |
| Stay Group | -10.8 |
(NCT00423878)
Timeframe: Measured at Month 6
| Intervention | participants (Number) |
|---|---|
| Switch Group | 22 |
| Stay Group | 18 |
Change in body weight in participants assigned to lorcaserin monotherapy treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin | -5.18 |
| Placebo | -3.02 |
Change in body weight in participants assigned to lorcaserin/metformin combination treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin and Metformin | -13.05 |
| Placebo | -3.02 |
fasting blood glucose (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -4.30 |
| Lorcaserin | -3.27 |
| Placebo | 3.53 |
high-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | 3.8 |
| Lorcaserin | 1.45 |
| Placebo | -0.78 |
glycosylated hemoglobin (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | percentage of glycosylated hemoglobin (Mean) |
|---|---|
| Lorcaserin and Metformin | -0.03 |
| Lorcaserin | 0.07 |
| Placebo | 0.05 |
low-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -7.60 |
| Lorcaserin | -10.86 |
| Placebo | -6.83 |
Total Cholesterol (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -9.05 |
| Lorcaserin | -13.45 |
| Placebo | -9.21 |
serum triglycerides (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -18.60 |
| Lorcaserin | -19.68 |
| Placebo | -3.11 |
"Body Image Software (BIS) - the subject adjusts a digital image of themselves on the computer to their desired image, and also completes a task that determines their perception of their current image. Accuracy is measured by a smaller score between desired image and actual image.~Change in BIS-DL was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points.~There are no identifiable minimum/maximum values as there would be in a questionnaire scale. There are no subscales. Interpreting the DL occurs by referencing it to DL= 0, which would reflect a total inability to detect size differences, which has never occurred in studies using the BIS program." (NCT00140426)
Timeframe: monthly
| Intervention | units on a scale (Mean) |
|---|---|
| Risperidone or Placebo | -0.19 |
| Risperidone | -1.16 |
"Body Image Software (BIS) - the subject adjusts a digital image of themselves on the computer to their desired image, and also completes a task that determines their perception of their current image. Accuracy is measured by a smaller score between desired image and actual image.~Change in BIS -PSE was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points.~There are no identifiable minimum/maximum values as there would be in a questionnaire scale. Interpreting the PSE is how it compares to a PSE = 0, which is no distortion in body size." (NCT00140426)
Timeframe: monthly
| Intervention | units on a scale (Mean) |
|---|---|
| Risperidone or Placebo | -0.32 |
| Risperidone | -2.18 |
"Body Image Software (BIS) - the subject adjusts a digital image of themselves on the computer to their desired image. The BIS program calculates the difference between their actual image, and how much they have adjusted the image to represent their desired image. Accuracy is measured by a smaller score between desired image and actual image.~Change in BIS - Average Desired Thinness score was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points.~There are no identifiable minimum/maximum values as there would be in a questionnaire scale. . There are no subscales." (NCT00140426)
Timeframe: monthly
| Intervention | units on a scale (Mean) |
|---|---|
| Risperidone or Placebo | 1.88 |
| Risperidone | -1.42 |
"Body Image Software (BIS) - the subject adjusts a digital image of themselves on the computer using the direction to adjust their image to how they see themselves right now, this determines their perception of their current image. Accuracy is measured by a smaller score between desired image and actual image.~Change in the BIS Average Distortion score during the study was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points.~There are no identifiable minimum/maximum values as there would be in a questionnaire scale. There are no subscales. The BIS program calculates the difference between their actual image and the size of the image they have adjusted the digital image to based on their perception of how they see themselves right now" (NCT00140426)
Timeframe: monthly
| Intervention | units on a scale (Mean) |
|---|---|
| Risperidone or Placebo | -0.22 |
| Risperidone | 1.40 |
"change in Eating Disorder Inventory (EDI) 2-score for Body Dissatisfaction (BD).~Lower scores are better on this scale. Higher scores indicate the subject has greater body dissatisfaction. BD is one of the 8 subscales of the EDI-2. 9 of the 91 questions in the EDI-2 scale constitute this subscale. The score range is 0-27. Subjects completed the EDI-2 at baseline and monthly during study participation (range 0 to 18 weeks). Change in the BD subscale score during the study was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points." (NCT00140426)
Timeframe: monthly
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.82 |
| Risperidone | 2.67 |
"Eating Disorder Inventory -2 - Subscale : Drive for Thinness Subscale (DT). Lower scores are better on this scale and indicate less cognitive focus on drive for thinness.~The EDI 2 is a 91 item scale with 8 subscales - (Drive for thinness, Bulimia, body dissatisfaction, ineffectiveness, perfection, interpersonal distrust, interoceptive awareness and maturity fears.). The DT subscale was used for this outcome. Respondents rate each item as usually , often, sometimes, rarely or never. Subscale scores are computed by summing all item scores for each subscale. There are 7 items in the DT subscale (questions 1,7,11,16,25,32 and 49). the subscale score range is 0-21. The EDI-2 was completed by subjects at baseline and then monthly during study participation (range 0 -18 weeks). Change in the DT subscale score was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points." (NCT00140426)
Timeframe: month
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 1.36 |
| Risperidone | 3.93 |
Leptin levels were measured by serum blood draws, results reports in nanograms / ml (ng/ml). (NCT00140426)
Timeframe: Week 0 and week 7
| Intervention | ng/ml (Mean) |
|---|---|
| Placebo | 0.88 |
| Risperidone | 3.27 |
Prolactin serum blood levels, measured in nanograms / ml (NCT00140426)
Timeframe: week 0 and week 7
| Intervention | ng/ml (Mean) |
|---|---|
| Placebo | -5.18 |
| Risperidone | 38.27 |
"The Multidimensional Anxiety Scale for Children (MASC) is a self report measure completed by the subject that measures anxiety symptoms.~Higher scores indicate greater anxiety. A score of over 50 is significant for anxiety~Change in MASC scores was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points." (NCT00140426)
Timeframe: monthly to study end point
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 7.41 |
| Risperidone | 7.87 |
"Color A Person Test (CAPT) - Subjects color an outlined image of a body to indicate body dissatisfaction (red (5)= very dissatisfied, Yellow, dissatisfied, black, neutral, green satisfied, blue very satisfied (1). The outline is divided into16 sections for scoring. The CAPT was completed at baseline and monthly during study participation.~Total CAPT scores were calculated by adding the total score and dividing by 16. Score range is 1-5. Lower scores indicate less body dissatisfaction.~Change in the CAPT score during the study was calculated using an estimate of change in score between week 0 and week 7 derived from the mixed effect model across all time points." (NCT00140426)
Timeframe: monthly
| Intervention | units on a scale (Mean) |
|---|---|
| Risperidone or Placebo | 0.03 |
| Risperidone | 0.22 |
"The Ease of Eating Scale (EOES) is a 14 item scale which measures Food avoidance behaviors (FABs). The scale is rated by staff observing a subject eating a meal or snack. 0 = normal eating behavior, maximum score 28.~Higher scores indicate more food avoidance behaviors, such as taking small bites, taking > 30 seconds between bites (slow eating), etc.~EOE was completed for each meal a subject ate in the program and scores were averaged for each week in the study and entered in the data base.~Change in EOES score was calculated by evaluating change over time. This measure was only used in Phase 1 of the study, for days the subjects were in the treatment program." (NCT00140426)
Timeframe: weekly up to study endpoint: reaching target weight and maintaining for 1 month
| Intervention | hazard ratio (Number) |
|---|---|
| Placebo | 0.85 |
| Risperidone | 1 |
The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time. These estimates were produced using Kaplan-Meier probabilities. (NCT00140426)
Timeframe: 0 - 18 weeks
| Intervention | weeks (Mean) |
|---|---|
| Placebo | 10.1 |
| Risperidone | 12.9 |
The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time. These estimates were produced using Kaplan-Meier probabilities. This was measured weekly from 0-18 weeks. (NCT00140426)
Timeframe: weekly
| Intervention | weeks (Mean) |
|---|---|
| Placebo | 10.7 |
| Risperidone | 8.1 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/L (Mean) |
|---|---|
| Pravastatin | 0.8063 |
| Placebo | -0.5136 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/dl (Mean) |
|---|---|
| Pravastatin | -25.565 |
| Placebo | -2.913 |
"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | 4.0417 |
| Placebo | 4.125 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -5.625 |
| Placebo | -3.76 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -0.83 |
| Placebo | -0.28 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -2.9583 |
| Placebo | -2.44 |
The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -9.416 |
| Placebo | -6.48 |
3 reviews available for risperidone and Body Weight
| Article | Year |
|---|---|
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 2003 |
Risperidone for bipolar disorders.
Topics: Antipsychotic Agents; Bipolar Disorder; Blood Glucose; Body Weight; Clinical Trials as Topic; Drug E | 2005 |
[Mechanisms of the body weight gain induced by novel antipsychotic drugs and concomitant lipid abnormalities].
Topics: Antipsychotic Agents; Body Weight; Clozapine; Dibenzothiazepines; Humans; Hyperlipidemias; Leptin; P | 2005 |
43 trials available for risperidone and Body Weight
| Article | Year |
|---|---|
A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Body Weight; Child; Child, Presch | 2014 |
Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year.
Topics: Adolescent; Adult; Antipsychotic Agents; Body Weight; Clozapine; Electrocardiography; Female; Follow | 2013 |
Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Body Weight; Cytokines; Female; Humans; Interleukin-1beta; | 2014 |
Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical t
Topics: Adjuvants, Pharmaceutic; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Diso | 2017 |
Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzoxazoles; Body Weight; Cholesterol; Dose-Response Re | 2008 |
Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment.
Topics: Adolescent; Anthropometry; Antidepressive Agents, Second-Generation; Body Mass Index; Body Size; Bod | 2010 |
Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Humans; Longitudinal | 2011 |
Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Body Weight; Brief Psychiatric Rating Scale; China; Di | 2011 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Chol | 2011 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Chol | 2011 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Chol | 2011 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Chol | 2011 |
A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study.
Topics: Adolescent; Adult; Anorexia Nervosa; Antipsychotic Agents; Body Image; Body Weight; Child; Double-Bl | 2011 |
Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania.
Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Wei | 2012 |
Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Appetite; Benzodiazepines; Body Weight; Female; Ghrelin; Humans; Male; | 2012 |
Hippocampal volume in schizophrenia and its relationship with risperidone treatment: a stereological study.
Topics: Adult; Algorithms; Antipsychotic Agents; Body Weight; Female; Functional Laterality; Hippocampus; Hu | 2002 |
A placebo-controlled trial of risperidone in Tourette syndrome.
Topics: Adolescent; Adult; Antipsychotic Agents; Body Weight; Child; Diagnostic Techniques, Neurological; Do | 2003 |
Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia.
Topics: Acute Disease; Adult; Age Factors; Age of Onset; Antipsychotic Agents; Body Weight; Dose-Response Re | 2003 |
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; Femal | 2003 |
Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Fasting; Fatty Acids, None | 2003 |
Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Autistic Disorder; Body Mass Index; Body Weight; Chil | 2004 |
Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 2004 |
The antidepressant effects of risperidone and olanzapine in bipolar disorder.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body W | 2004 |
[Incidence of rigor during treatment with flupentixol decanoate in comparison to risperidone].
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Body Weight; Cross-Sectio | 2004 |
Long-acting risperidone in stable patients with schizoaffective disorder.
Topics: Adult; Aged; Antipsychotic Agents; Body Weight; Delayed-Action Preparations; Female; Humans; Injecti | 2005 |
Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Delayed-Action Preparati | 2005 |
Acute and long-term safety and tolerability of risperidone in children with autism.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Autistic Disorder; Body M | 2005 |
Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; Estradiol; Female; Galactorrhea; Gynecomastia; H | 2006 |
Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Blood Pressure; Body Mass Index; Bod | 2005 |
A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; | 2006 |
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Chronic Disease; Cross-Over Studies; Dibe | 2006 |
Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Chronic Disease; Double-Blind Method; Fem | 2006 |
An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Body Weight; Child; Dose | 2006 |
Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Body Weight; Dose-Response Relationship | 2007 |
Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Body Weight; Child; Child Nutritional Physiolog | 2006 |
Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone.
Topics: Administration, Oral; Adult; Body Weight; Cardiovascular System; Female; Hospitalization; Humans; In | 2007 |
Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders.
Topics: Antipsychotic Agents; Body Mass Index; Body Weight; Chlorpromazine; Female; Follow-Up Studies; Human | 2007 |
Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Body Weight; Clozapine; Femal | 2007 |
Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment.
Topics: Antipsychotic Agents; Body Weight; Clozapine; Data Interpretation, Statistical; Double-Blind Method; | 2007 |
Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.
Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Diagnosti | 2007 |
Risperidone and liver function tests in children and adolescents: a short-term prospective study.
Topics: Adolescent; Alanine Transaminase; Alkaline Phosphatase; Antipsychotic Agents; Aspartate Aminotransfe | 2008 |
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.
Topics: Absorptiometry, Photon; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Blood Gl | 2008 |
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothi | 2008 |
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Body Weight; Double-Blind Method; Female; H | 1999 |
A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Body Weight; | 2000 |
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Appetite; Benzodiazepines; Body Mass Index; Body Weight; B | 2001 |
63 other studies available for risperidone and Body Weight
| Article | Year |
|---|---|
Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.
Topics: Animals; Antipsychotic Agents; Body Weight; Chemistry Techniques, Synthetic; Drug Design; Ether-A-Go | 2018 |
Effects of Early Risperidone Treatment on Metabolic Parameters in Socially Isolated Rats-Implication of Antipsychotic Intervention across Developmental Stages of Schizophrenia.
Topics: Animals; Antipsychotic Agents; Body Weight; Insulin Resistance; Insulins; Rats; Risperidone; Schizop | 2023 |
Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Humans; Olanzapine; Risperidone; S | 2023 |
The effect of bezafibrate in preventing glucolipid abnormalities induced by the antipsychotic risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Bezafibrate; Blood Glucose; Body Weight; Drug Therapy, Comb | 2019 |
Effects of long-term antipsychotics treatment on body weight: A population-based cohort study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Body Weight; Cohort S | 2020 |
Risperidone stimulates food intake and induces body weight gain via the hypothalamic arcuate nucleus 5-HT2c receptor-NPY pathway.
Topics: Animals; Arcuate Nucleus of Hypothalamus; Body Weight; Eating; Female; Mice; Mice, Inbred C57BL; Neu | 2020 |
Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice.
Topics: Adipocytes; Adiponectin; Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Ca | 2021 |
The effect of prohibiting outside food during COVID-19 pandemic on the body weight of schizophrenic patients taking olanzapine or clozapine: a retrospective self-controlled study.
Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; China; Clozapine; COVID-19; Humans; Olanzapine; | 2021 |
Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Biomarkers; Body Weight; Feces; Female; Gastrointestinal Microbiome; Hu | 2018 |
Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Body Weight; Cohort Studies; Databases, Factua | 2018 |
Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Body Weight; Child; Female; Humans; | 2019 |
Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor.
Topics: Animals; Antipsychotic Agents; Body Weight; Female; Ghrelin; Hyperglycemia; Leptin; Mice; Mice, Inbr | 2019 |
Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies.
Topics: Adolescent; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Amidohydrolases; Antipsychotic Agents; Bo | 2013 |
A 12-week intramuscular toxicity study of risperidone-loaded microspheres in Beagle dogs.
Topics: Animals; Antipsychotic Agents; Blood Pressure; Body Temperature; Body Weight; Dogs; Dopamine Antagon | 2014 |
Lower risk for body weight gain and better control of appetite after switching risperidone to paliperidone in a schizoaffective patient.
Topics: Adult; Antipsychotic Agents; Appetite; Body Weight; Female; Humans; Isoxazoles; Paliperidone Palmita | 2014 |
A 12-week subchronic intramuscular toxicity study of risperidone-loaded microspheres in rats.
Topics: Animals; Antipsychotic Agents; Body Weight; Delayed-Action Preparations; Dopamine Antagonists; Femal | 2015 |
Vitamin D deficiency exacerbates atypical antipsychotic-induced metabolic side effects in rats: involvement of the INSIG/SREBP pathway.
Topics: Animals; Antipsychotic Agents; Body Weight; Clozapine; Disease Models, Animal; Eating; Glucose Intol | 2015 |
Antipsychotic-induced metabolic effects in the female rat: Direct comparison between long-acting injections of risperidone and olanzapine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Half-Life; Olanzapine; Rats; Ra | 2015 |
The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Body Weight; Child; Child, Preschool; Female; Fol | 2017 |
Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Body Weight; Child; Child, Pres | 2008 |
Repeated risperidone administration during puberty prevents the generation of the aggressive phenotype in a developmentally immature animal model of escalated aggression.
Topics: Age Factors; Aggression; Animals; Animals, Newborn; Antipsychotic Agents; Behavior, Animal; Body Wei | 2008 |
Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Biological Availability; Body Wei | 2008 |
Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course.
Topics: Adolescent; Adult; Age Factors; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Body Ma | 2009 |
Risperidone-associated increase in triglyceride levels.
Topics: Adult; Antipsychotic Agents; Body Weight; Dose-Response Relationship, Drug; Humans; Hypercholesterol | 2009 |
Effect of lactational exposure of olanzapine on body weight of mice: a comparative study on neonates of both the sexes during post-natal development.
Topics: Animals; Animals, Newborn; Animals, Suckling; Antipsychotic Agents; Benzodiazepines; Body Weight; Fe | 2010 |
Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome.
Topics: Adolescent; Adolescent Development; Age Factors; Analysis of Variance; Antipsychotic Agents; Body Co | 2009 |
Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Eating; Male; Mice; Mic | 2010 |
Successful risperidone treatment for behavioral disturbances in Prader-Willi syndrome.
Topics: Aggression; Antipsychotic Agents; Body Mass Index; Body Weight; Child; Child Behavior Disorders; Chr | 2010 |
Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Clozapine; Female; Genes; Genotype; Haplo | 2010 |
Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Cross-Sectio | 2010 |
The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Antipsychotic Agents; Benzimidazol | 2010 |
Six months of treatment with risperidone may be associated with nonsignificant abnormalities of liver function tests in children and adolescents: a longitudinal, observational study from Turkey.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Body Weight; | 2010 |
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Topics: Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibe | 2011 |
Effects of risperidone, quetiapine and ziprasidone on ethanol withdrawal syndrome in rats.
Topics: Alcoholism; Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Central Nervous System Dep | 2011 |
Some effects of risperidone and quetiapine on growth parameters and hormone levels in young pigtail macaques.
Topics: Age Factors; Animals; Antipsychotic Agents; Body Weight; Bone and Bones; Bone Density; Child; Child, | 2010 |
The effect of long-term use of risperidone on body weight of children with an autism spectrum disorder.
Topics: Antipsychotic Agents; Body Weight; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disrupti | 2011 |
Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Clozapine; | 2012 |
Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Body Composition; Body Weight; Corticosterone; Eating; | 2002 |
Weight change after an atypical antipsychotic switch.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; | 2003 |
Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection.
Topics: Adipocytes; Adipose Tissue; Animals; Antipsychotic Agents; Body Composition; Body Weight; Cell Count | 2004 |
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine | 2005 |
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine | 2005 |
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine | 2005 |
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine | 2005 |
Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Dietary Fats; Dogs; Ins | 2005 |
Antipsychotic drug-induced weight gain: development of an animal model.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Constitution; Body Weight; Dibenzothiazepines; | 2005 |
Resistance to excessive bodyweight gain in risperidone-injected rats.
Topics: Adipose Tissue; Adipose Tissue, Brown; Animals; Body Temperature; Body Weight; Gene Expression; Gene | 2005 |
Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate.
Topics: Adult; Anti-Obesity Agents; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Chi | 2005 |
A crossover study on lipid and weight changes associated with olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Cross-Ove | 2005 |
Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study.
Topics: Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weig | 2006 |
Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Appetite; Body Weight; Corticosterone; Diabetes Melli | 2006 |
Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Body Weight; Child; Clozapine; Female; Humans; Ma | 2007 |
Weight development in patients treated with risperidone: a 5-year naturalistic study.
Topics: Adult; Aged; Antipsychotic Agents; Body Weight; Female; Follow-Up Studies; Humans; Male; Middle Aged | 2007 |
Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Body Weight; Chlorpromazine; Clozapine; Dopamine; Dyskinesia, Drug-In | 2007 |
Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Drug A | 2008 |
The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats.
Topics: Adiposity; Animals; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Composition; Body Wei | 2007 |
Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets.
Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weigh | 2007 |
Distinct neurobehavioral consequences of prenatal exposure to sulpiride (SUL) and risperidone (RIS) in rats.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Brain; Conditioning, Psychological; Di | 2008 |
Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents.
Topics: Adolescent; Adult; Aging; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Body Weight; Chil | 2007 |
Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Body Image; Body Weight; Catatonia; Cyclobutanes; | 2008 |
Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Body Weight; Dibenzothiazepines; Dose-Resp | 2008 |
Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration.
Topics: Animals; Antipsychotic Agents; Body Weight; Brain; Brain-Derived Neurotrophic Factor; Feeding Behavi | 2000 |
Atypical antipsychotics and cardiovascular risk in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Cardiovascular Diseases; Cross-Sectional | 2001 |
[Schizophrenia and diabetes alliance. No increased insulin resistance due to risperidone].
Topics: Body Weight; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Male; Risperidone; Schiz | 2001 |
A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
Topics: Adult; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Dia | 2002 |